NASDAQ : TERN
Terns Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 52.95 USD (At close: May 4, 2026) · Market cap 6.11B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 6.11B |
| Enterprise Value | 5.10B |
Dates
| Measure | Value |
|---|
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 115.46M |
| Shares Outstanding | 115.46M |
| Shares Change (YoY) | +17.18% |
| Shares Change (QoQ) | +6.77% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 105.52% |
| Float | 115.17M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.91 |
| P/TBV Ratio | 6.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 62.41 |
| Quick Ratio | 62.09 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -14.23% |
| Return on Assets (ROA) | -9.91% |
| Return on Invested Capital (ROIC) | -10.16% |
| Return on Capital Employed (ROCE) | -10.92% |
| Weighted Average Cost of Capital (WACC) | 2.16% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.63M |
| Employee Count | 59 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 581,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.38 |
| 52-Week Price Change | +1,412.86% |
| 50-Day Moving Average | 49.21 |
| 200-Day Moving Average | 27.75 |
| Relative Strength Index (RSI) | 73.93 |
| Average Volume (20 Days) | 6,312,927 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 8.06M |
| Short Previous Month | 13.51M |
| Short % of Shares Out | 6.98% |
| Short % of Float | 7.00% |
| Short Ratio (days to cover) | 0.70 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -110.12M |
| Pretax Income | -95.63M |
| Net Income | -96.21M |
| EBITDA | -110.03M |
| EBIT | -110.12M |
| Earnings Per Share (EPS) | -$1.03 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.02B |
| Total Debt | 919,000 |
| Net Cash | 1.02B |
| Net Cash Per Share | $8.82 |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 8.96 |
| Working Capital | 1.01B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -82.18M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 90,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -82.18M |
| FCF Per Share | -$0.71 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.18% |
| Shareholder Yield | -17.18% |
| Earnings Yield | -1.57% |
| FCF Yield | -1.34% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $45.22 |
| Price Target Difference | -14.60% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |